Novavax Inc. (NASDAQ:NVAX) had its target price lowered by FBR & Co from $17.00 to $12.00 in a report issued on Friday. The firm currently has an outperform rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the stock. Vetr raised shares of Novavax from a buy rating to a strong-buy rating and set a $8.66 target price on the stock in a research report on Tuesday, August 23rd. Guggenheim reissued a buy rating and set a $25.00 target price on shares of Novavax in a research report on Monday, August 29th. Piper Jaffray Cos. reissued an overweight rating and set a $14.00 target price on shares of Novavax in a research report on Friday, September 9th. Wedbush cut shares of Novavax from an outperform rating to a neutral rating and reduced their target price for the stock from $14.00 to $2.00 in a research report on Friday, September 16th. Finally, Citigroup Inc. boosted their target price on shares of Novavax from $10.00 to $12.00 and gave the stock a buy rating in a research report on Thursday, July 28th. Seven analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Novavax has a consensus rating of Hold and a consensus price target of $7.06.

Shares of Novavax (NASDAQ:NVAX) opened at 1.94 on Friday. The firm’s market cap is $525.42 million. Novavax has a 52 week low of $1.16 and a 52 week high of $9.56. The company’s 50-day moving average is $6.69 and its 200-day moving average is $6.16.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.04. The business had revenue of $2.50 million for the quarter, compared to analyst estimates of $8.03 million. Novavax had a negative net margin of 1,405.84% and a negative return on equity of 112.45%. The company’s quarterly revenue was down 82.1% on a year-over-year basis. During the same period last year, the firm earned ($0.08) earnings per share. Analysts forecast that Novavax will post ($1.09) EPS for the current fiscal year.

In other Novavax news, Director Gail Boudreaux bought 100,000 shares of the stock in a transaction on Tuesday, September 20th. The stock was purchased at an average price of $1.45 per share, for a total transaction of $145,000.00. Following the completion of the purchase, the director now directly owns 200,000 shares in the company, valued at $290,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 3.50% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. IFP Advisors Inc raised its stake in Novavax by 18.4% in the second quarter. IFP Advisors Inc now owns 33,500 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 5,204 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in Novavax by 4.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 959,708 shares of the biopharmaceutical company’s stock valued at $6,978,000 after buying an additional 36,684 shares during the last quarter. Stifel Financial Corp raised its stake in Novavax by 1.9% in the second quarter. Stifel Financial Corp now owns 21,990 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 400 shares during the last quarter. Amalgamated Bank raised its stake in Novavax by 1.1% in the second quarter. Amalgamated Bank now owns 28,525 shares of the biopharmaceutical company’s stock valued at $196,000 after buying an additional 300 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in Novavax by 16.0% in the second quarter. Legal & General Group Plc now owns 70,431 shares of the biopharmaceutical company’s stock valued at $510,000 after buying an additional 9,694 shares during the last quarter. Hedge funds and other institutional investors own 79.84% of the company’s stock.

Novavax Company Profile

Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.

5 Day Chart for NASDAQ:NVAX

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.